focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 330.50
Bid: 331.50
Ask: 332.00
Change: 3.00 (0.92%)
Spread: 0.50 (0.151%)
Open: 332.00
High: 336.00
Low: 321.00
Prev. Close: 327.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Financial Officer

26 Nov 2021 07:00

RNS Number : 6555T
Synthomer PLC
26 November 2021
 

26th November 2021

 

Synthomer plc

 

Appointment of Chief Financial Officer

 

 

Synthomer plc ("Synthomer" or "the Company") today announces the appointment of Lily Liu as Chief Financial Officer (CFO). Lily will take up the role no later than 1 July 2022, succeeding Steve Bennett who announced in August 2021 that he would step down once a suitable successor was in place.

Lily is a highly experienced CFO with an impressive track record of building strong performing finance teams and creating business value through organic and inorganic growth. She has worked in the manufacturing and engineering sectors for over 20 years, and joins from Essentra plc, a FTSE 250 components and solutions business, where she has been CFO. Lily was previously CFO at Xaar plc, a UK listed inkjet technology developer, and Smiths Detection business, a division of Smiths Group plc. Lily was born in Beijing and holds a degree in Economics from the Shanghai University of International Business & Economics. She moved to Sydney, Australia where she completed an MBA and developed her career with an investment bank before joining the BOC group, with whom she had a varied and successful career and moved to work in the UK in 2003.

Lily is currently a Non-Executive Director and member of the Audit Committee of DCC plc, a FTSE 100 listed international sales, marketing and support services business.

Commenting, Michael Willome, Chief Executive Officer, said:

"I am delighted that Lily has accepted the Board's offer to join Synthomer as Chief Financial Officer. She has a proven track record as a CFO and brings wide international business experience, having worked in the UK, Australia and Asia. I look forward to working with her to continue delivering on Synthomer's value creation agenda. I would also like to thank Steve for his enormous contribution and commitment to the Company, and wish him every success for the future."

Lily Liu added:

"I am very pleased to be joining Synthomer at an exciting point in the Company's development following the acquisition of the Eastman Adhesives Resins business in 2022. I look forward to working with Michael and the team on delivering the integration benefits and building on the considerable success which Synthomer has achieved to date." 

There are no other details that are required to be disclosed under Listing Rule 9.6.13.

Remuneration

All remuneration arrangements for Lily are consistent with the terms of the Directors' Remuneration Policy approved by shareholders at the AGM in April 2020. Lily will receive a base salary of £440,000 per annum. She will receive a pension allowance in line with the UK workforce. Lily will participate in the current Executive Director Annual Bonus Plan, which has an annual award opportunity of 150% of base salary (one-third deferred into shares for two years). She will participate in the Synthomer Performance Share Plan with an annual award opportunity of 150% of base salary, subject to performance conditions measured over a three-year period, with an additional two years holding period. She will be eligible to participate in both schemes in 2022. Lily will be required to build a shareholding equal to 200% of annual basic salary.

Lily will be entitled to benefits in line with the Group's current policy. Lily's employment contract requires 12 months' notice of termination by her and the Company.

 

Further information

Tim Hughes, President, Corporate Development Tel: 01279 436211

Charles Armitstead, Teneo Tel: 07703 330 269

 

ENDS

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUVUBRAKUAUAA
Date   Source Headline
16th Jun 202010:11 amRNSQ2 trading update
11th May 20205:21 pmRNSHolding(s) in Company
11th May 20209:03 amRNSDirector/PDMR Shareholding
11th May 20209:02 amRNSDirector/PDMR Shareholding
11th May 20208:59 amRNSDirector/PDMR Shareholding
11th May 20208:58 amRNSDirector/PDMR Shareholding
29th Apr 20203:17 pmRNSResult of AGM
29th Apr 20207:00 amRNSQ1 Trading and COVID-19 Update
1st Apr 20202:44 pmRNSCompletion of OMNOVA acquisition
1st Apr 20207:00 amRNSAnnual Financial Report
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:00 amRNSAppointment of Deputy Chair and Chair-elect
30th Mar 20207:00 amRNSDirector/PDMR Shareholding
26th Mar 202010:17 amRNSEuropean Commission clearance for OMNOVA
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
16th Mar 20209:50 amRNSDirector/PDMR Shareholding
13th Mar 20205:29 pmRNSDirector/PDMR Shareholding
9th Mar 20202:45 pmRNSHolding(s) in Company
5th Mar 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019
31st Jan 20209:36 amRNSDirector Declaration
15th Jan 20202:21 pmRNSAcquisition of OMNOVA receives EC clearance
6th Dec 20197:00 amRNSAppointment of Broker
13th Nov 20192:53 pmRNSDirector/PDMR Shareholding
11th Nov 20197:00 amRNSDirector Declaration
25th Oct 20197:00 amRNSQ3 Trading Update
22nd Oct 20197:00 amRNSAGM Statement
11th Oct 20197:00 amRNSOmnova shareholders approval
14th Aug 20193:25 pmRNSHolding(s) in Company
13th Aug 201912:33 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results for 6 months ended 30 June 2019
2nd Aug 201910:29 amRNSHolding(s) in Company
1st Aug 20199:05 amRNSHolding(s) in Company
31st Jul 201910:51 amRNSResults of Extraordinary General Meeting
30th Jul 20191:07 pmRNSDirector/PDMR Shareholding
30th Jul 20191:03 pmRNSDirector/PDMR Shareholding
30th Jul 20191:02 pmRNSDirector/PDMR Shareholding
30th Jul 20191:01 pmRNSDirector/PDMR Shareholding
30th Jul 201912:59 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:57 pmRNSDirector/PDMR Shareholding
30th Jul 201912:55 pmRNSDirector/PDMR Shareholding
30th Jul 201912:54 pmRNSDirector/PDMR Shareholding
30th Jul 201912:53 pmRNSDirector/PDMR Shareholding
30th Jul 201912:52 pmRNSDirector/PDMR Shareholding
30th Jul 201912:51 pmRNSDirector/PDMR Shareholding
30th Jul 201912:50 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201911:31 amRNSResults of Rump Placing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.